It was shown that the extracellular domain of SORL1 interacts directly with HER2 and HER3, and an antibody targeting the extracellular domain of SORL1 (Figure 4A) can disrupt its ability to support HER2/HER3 trafficking in breast cancer cells [7,8]. This evidence concerns the gene ERBB2 and breast carcinoma.